Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Fulgent Pharma LLC.
University of Chicago
Gilead Sciences
Ohio State University Comprehensive Cancer Center
National Medical Research Radiological Centre of the Ministry of Health of Russia
University of Chicago
Wake Forest University Health Sciences
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Grupo EspaƱol de Tratamiento de Tumores de Cabeza y Cuello
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
Iovance Biotherapeutics, Inc.
University of Michigan Rogel Cancer Center
University of Chicago
Medical University of Vienna
University of Chicago
Thomas Jefferson University
Replimune Inc.
Ohio State University Comprehensive Cancer Center
Latin American Cooperative Oncology Group
West China Hospital
The First Affiliated Hospital with Nanjing Medical University
University of Chicago
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lyvgen Biopharma Holdings Limited
Centre Leon Berard
Rutgers, The State University of New Jersey
Sun Yat-sen University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Bristol-Myers Squibb
Ohio State University Comprehensive Cancer Center
University of California, Davis
Grupo EspaƱol de Tratamiento de Tumores de Cabeza y Cuello
UNC Lineberger Comprehensive Cancer Center
University of Chicago
First Affiliated Hospital of Zhejiang University
University of Maryland, Baltimore
Grupo EspaƱol de Tratamiento de Tumores de Cabeza y Cuello
Jonsson Comprehensive Cancer Center